Literature DB >> 2629021

Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers.

G L Bird1, H Smith, B Portmann, G J Alexander, R Williams.   

Abstract

Five chronic carriers of hepatitis B virus developed a fulminant hepatitis-like picture when immunosuppression or cytotoxic treatment, given for unrelated disorders, was withdrawn. Viral replication at the time of the final illness was confirmed in three of the five cases by measurement of serum HBV DNA or the presence of HBc antigen on liver biopsy. A cytoplasmic and nuclear pattern of HBc was seen in histological material during life, but at post-mortem was limited to a nuclear distribution, suggesting greater destruction of hepatocytes containing cytoplasmic HBc. In two of the cases, chronic liver disease was found at post-mortem, there being no previous clinical or laboratory abnormality, but it is unlikely that this was a factor in the development of the superimposed fulminating hepatitis-like illness. Immunosuppressive and cytotoxic agents must be used with extreme caution in any hepatitis B carrier, as withdrawal can precipitate acute decompensation regardless of whether or not there is underlying chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2629021

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  19 in total

1.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

2.  Reactivation of hepatitis B virus in a previously immune patient with human immunodeficiency virus infection.

Authors:  B Vandercam; C Cornu; J L Gala; A Geubel; M Cahill; M E Lamy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

Review 3.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 4.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

Review 5.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 6.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 7.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

8.  Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.

Authors:  C-K Hui; W W W Cheung; W-Y Au; A K W Lie; H-Y Zhang; Y-H Yueng; B C Y Wong; N Leung; Y-L Kwong; R Liang; G K K Lau
Journal:  Gut       Date:  2005-07-06       Impact factor: 23.059

9.  The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma.

Authors:  Jawad Ahmad; John Rhee; Brian I Carr
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

10.  Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.

Authors:  F ter Borg; S Smorenburg; R A de Man; R C Rietbroek; R A Chamuleau; E A Jones
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.